Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults with Type 2 Diabetes
The Woodlands, Texas, December 30, 2021– Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | Heart | Heart Failure | Marketing | New Drug Applications